The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I substance in the United States, meaning the only legal access pathways are through active...
Psilocybin grief therapy is an emerging, clinically-studied approach for individuals whose grief has persisted well beyond the expected acute phase. For high-functioning professionals who have maintained performance while carrying unprocessed loss, the evidence points...
Psychedelic policy in the USA is moving faster in 2026 than at any point in recent history. A federal executive order, a wave of state-level bills, and advancing clinical trials have all converged in the first half of this year. This guide covers the key federal...
Research into psilocybin sleep insomnia effects is still early, but the findings are genuinely interesting. Studies show psilocybin alters REM sleep and slow-wave activity in ways that parallel some antidepressants, and preliminary data suggests sleep quality may...
Psilocybin eating disorder treatment is an emerging area of clinical research, with early trials in anorexia nervosa showing that the compound is well-tolerated and may help shift entrenched psychological patterns. The data is preliminary, the sample sizes are small,...
Ketamine vs. esketamine (Spravato) is one of the most common points of confusion for people exploring treatment-resistant depression options. Both work through a similar mechanism in the brain, but they differ in molecular composition, route of administration, FDA...
